Lung cancer EGFR — Patients


The therascreen EGFR test reliably detects mutations of the EGFR gene, which are found in non-small cell lung cancer.
Information for Patients
  • Main Image Navi

The therascreen EGFR test:

  • The FDA-approved test for EGFR mutation detection
  • Helps determine if you can benefit from either GILOTRIF (afatinib) or IRESSA (gefitinib) treatment

Ask your oncologist for the FDA-approved therascreen EGFR test.

Non-small cell lung cancer
About the therascreen EGFR test
Understanding insurance coverage

Back to top Non-small cell lung cancer (NSCLC)

What is non-small cell lung cancer?

  • NSCLC is 1 of 2 major types of lung cancer, which  accounts for 85%-90% of lung cancers

The two major types of lung cancer grow and spread in different ways and may have different treatment options, so a distinction between these two types is important. Among treatment options for patients diagnosed with NSCLC, new treatments, called targeted therapies are now available and approved. However, studies have found that only some patients benefit from certain targeted therapies. A test can find changes in the EGFR gene that make it more likely that a person’s lung cancer will respond to treatment with an EGFR inhibitor like either GILOTRIF (afatinib) or IRESSA (gefitinib). Determining who might benefit could save some people from trying treatments that are unlikely to work for them.

Back to topAbout the therascreen EGFR test

The therascreen EGFR test reliably detects mutations, or changes, in the EGFR gene within your NSCLC tumor. The status of the EGFR gene helps your oncologist determine the best method of treatment.

  • If your EGFR gene status is not normal, then you may benefit from either GILOTRIF (afatinib) or IRESSA (gefitinib) treatment
  • If your EGFR gene is normal, your doctor will determine an appropriate alternative treatment

If you, or someone you know, have been diagnosed with NSCLC, ask your oncologist about the FDA approved EGFR test for patients with NSCLC, the therascreen EGFR test.

Back to topUnderstanding insurance coverage

The therascreen EGFR test:

  • Is FDA-approved for the detection of mutations in the EGFR gene
  • Helps identify which patients might be helped by either GILOTRIF (afatinib) or IRESSA (gefitinib) treatment

Public and private payers endorse the value of EGFR testing with strong coverage policies for approved indications.

QIAGEN has a broad portfolio of companion diagnostic products in development.


You are not authorized to download the resource

External Links
The nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem.
Information about lung cancer from the National Institutes of Health.
Information about lung cancer (one of the National Institutes of Health).